Monographie - Ertapenem

最新更新 :
08/05/2024

Ertapenem

化学式

商品名

商品名仅供参考, 药品所用的辅料可能依国家或厂商不同有所不同。

Ertacrit	印度
Ertagram	秘鲁
Ertamac	印度
Invanz	丹麦, 冰岛, 加拿大, 匈牙利, 卢森堡, 厄瓜多尔, 哥伦比亚, 土耳其, 埃及, 墨西哥, 奥地利, 委内瑞拉, 巴西, 希腊, 德国, 意大利, 挪威, 摩洛哥, 新西蘭, 日本, 智利, 法国, 波兰, 澳大利亚, 爱尔兰, 瑞典, 瑞士, 秘鲁, 罗马尼亚, 美国, 芬兰, 英国, 荷兰, 葡萄牙, 西班牙, 阿根廷, 阿联酋, 马来西亚
Lyortam	智利, 秘鲁

引用文献 : Ertapenem

	种类	出版物
1906	文献	McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ. Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions. Am J Health-Syst Pharm 2004 ; 61: 38-45.
1912	实验室	Ertapenem (Invanz®) - Summary of Product Characteristics Merck Sharp Dohme 2016
1982	文献	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2178	文献	Zajac M, Cielecka-Piontek J, Jelinska A. Stability of ertapenem in aqueous solutions. J Pharm Biomed Anal 2007 ; 43: 445-449.
2247	文献	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3208	文献	Phipps Stephen D, Peacock Gina F, Smith Douglas L . Stability of Ertapenem in an Elastomeric Infusion Device. Int J Pharm Compound 2011 ; 15, 3: 252-254.
3254	文献	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3549	实验室	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3674	实验室	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3717	文献	Jain J.G, Sutherland C, Nicolau D.P, Kuti J.L. Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C. Am J Health-Syst Pharm 2014 ; 71:1480-1484
3824	文献	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	海报	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	海报	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	海报	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3891	文献	Walker S.E, Law S, Perks W, Iazzetta J. Stability of Ertapenem 100 mg/mL in Manufacturer’s Glass Vials or Syringes at 4°C and 23°C Can J Hosp Pharm 2015 ; 68, 2: 121-126.
3997	文献	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055	文献	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	文献	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	文献	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4528	文献	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4742	文献	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	文献	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales